Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Renal and urinary disorders – page 9

  • 591 clinical trials
  • 223 recruiting
  • 296 conditions
  • 27 countries

Conditions in this area

296 conditions with trials, the busiest first

Chronic kidney disease64Bladder cancer55Transitional cell carcinoma47Renal cell carcinoma42Bladder transitional cell carcinoma34IgA nephropathy24Acute kidney injury21Non-small cell lung cancer19Urinary tract infection19Lupus nephritis18Clear cell renal cell carcinoma17Paroxysmal nocturnal haemoglobinuria17Breast cancer14Metastatic renal cell carcinoma14End stage renal disease13Congenital cystic kidney disease12Colorectal cancer11Endometrial cancer11Hepatocellular carcinoma11Malignant melanoma11Nephrotic syndrome11Ovarian cancer11Glomerulonephritis membranous10Kidney transplant rejection10+272

Clinical trials in Renal and urinary disorders

591 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

591 clinical trials

Urethral valves

Recruiting

Study on the Effectiveness and Safety of Circumcision and Antibiotic Treatment (Cefaclor, Sulfamethoxazole, Trimethoprim) for Boys with Posterior Urethral Valves

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Amoxicillin
  • Sponsor:Centre Hospitalier Universitaire De Bordeaux

Urinary tract infection

Recruiting

Study on Fecal Microbiota Transfer for Preventing Recurrent Urinary Tract Infections in Premenopausal Women Using Intestifix

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Ascorbic Acid
  • Sponsor:Goethe University Frankfurt

Bladder cancer

Recruiting

Study on the Effectiveness of Hexaminolevulinate in Bladder Cancer Surgery for Patients with Non-Muscle Invasive Bladder Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Hexaminolevulinate
  • Sponsor:Azienda Ospedaliera Universitaria Citta Della Salute E Della Scienza Di Torino

Primary hyperoxaluria

Recruiting

Study on the Safety and Effects of ABO-101 with mRNA-002 and gRNA-001 for Patients with Primary Hyperoxaluria Type 1

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:GRNA-001
  • Sponsor:Arbor Biotechnologies Inc.

Acute kidney injury+1

Recruiting

Study of hydrocortisone and fludrocortisone in patients with intermediate/high-risk scheduled cardiac surgery to prevent complications

Registered drug
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Fludrocortisone
  • Sponsor:Centre Hospitalier Universitaire Amiens Picardie

Alagille syndrome+1

Recruiting

Study on Long-Term Safety and Effects of Maralixibat for Patients with Alagille Syndrome

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Maralixibat
  • Sponsor:Mirum Pharmaceuticals Inc.

Bladder cancer

Recruiting

Study of mRNA-4157 and BCG for Patients with High-Risk Non-Muscle Invasive Bladder Cancer

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157
  • Sponsor:Merck Sharp & Dohme LLC

Chronic kidney disease

Recruiting

Study on Dapagliflozin, Finerenone, and Semaglutide for Treating Chronic Kidney Disease in Patients

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Finerenone
  • Sponsor:Steno Diabetes Center Copenhagen

End stage renal disease+1

Recruiting

Study on Mannitol and Normal Saline for Patients with End-Stage Renal Disease Undergoing Kidney Transplantation

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Mannitol
  • Sponsor:HUS-Yhtymae

Granulomatosis with polyangiitis

Recruiting

Study on Obinutuzumab for Patients with Relapsing Granulomatosis with Polyangiitis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Assistance Publique Hopitaux De Paris

Lupus nephritis

Recruiting

Study on the Effects and Safety of Ianalumab in Adults with Lupus Nephritis Who Completed Previous Treatment

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

Urinary incontinence+7

Recruiting

Study on the Effects of Vaginal Estrogen Treatment with Nomegestrol Acetate and Estradiol Hemihydrate on Blood Clotting in Postmenopausal Women with Vaginal Atrophy

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Nomegestrol Acetate
  • Sponsor:Aarhus University Hospital

Substances studied in this area

The therapies tested most often in Renal and urinary disorders trials.

Pembrolizumab54 clinical trialsNivolumab36 clinical trialsDapagliflozin25 clinical trialsMycophenolate Mofetil24 clinical trialsCabozantinib22 clinical trialsCisplatin22 clinical trialsIpilimumab21 clinical trialsGemcitabine20 clinical trialsSodium Chloride17 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.